Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
Marco Matucci-Cerinic, Yannick Allanore, Arthur Kavanaugh, Maya H Buch, Hendrik Schulze-Koops, Eugeniusz J Kucharz, Heike Woehling, Goran Babic, Johann Poetzl, Adanna Davis, Arnd Schwebig
RMD Open Nov 2018, 4 (2) e000757; DOI: 10.1136/rmdopen-2018-000757